studies

522A AASLD ABSTRACTS HEPATOLOGY, October, 2015
Disclosures:
Kris V. Kowdley - Advisory Committees or Review Panels: Achillion, BMS, Evidera,
Gilead, Merck, Novartis, Trio Health, Abbvie; Grant/Research Support:
Evidera, Gilead, Immuron, Intercept, Tobira; Speaking and Teaching: Abbvie,
Gilead
Hemant Shah - Advisory Committees or Review Panels: Boehringer-Ingelheim;
Consulting: Hoffman La-Roche, Merck, Gilead; Speaking and Teaching: Vertex
Andrew Mason - Advisory Committees or Review Panels: AbbVie, Novartis,
Intercept; Grant/Research Support: Abbvie, Gilead, Astellas
Richard Pencek - Employment: Intercept Pharmaceuticals; Stock Shareholder:
Intercept Pharmaceuticals
Tonya Marmon - Employment: Intercept Pharmaceuticals, Inc; Stock Shareholder:
Intercept Pharmaceuticals, Inc
David Shapiro - Employment: Inttercept Pharmaceuticals; Management Position:
Intercept Pharmaceuticals; Stock Shareholder: Intercept Pharmaceuticals
Roya Hooshmand-Rad - Employment: Intercept pharmaceuticals Inc.
The following authors have nothing to disclose: Velimir A. Luketic
629
Thyroid dysfunction in primary biliary cirrhosis: a comparative
study at two European centers.
Chiara Mangini 1 , Ana Reig 2 , Irene Franceschet 1 , Nora Cazzagon
1 , Lisa Perini 1 , Llorenç Caballeria 2 , Silvia Cocchio 3 , Vincenzo
Baldo 3 , Albert Pares 2 , Annarosa Floreani 1 ; 1 Department of Surgery,
Oncology and Gastroenterology, University of Padova,
Padova, Italy; 2 Liver Unit, Hospital Clinic-IDIBAPS, University of
Barcelona, Barcelona, Spain; 3 Department of Molecular Medicine,
Laboratory of Public Health and Population Studies, University of
Padova, Padova, Italy
Primary Biliary Cirrhosis (PBC) is often associated with other
autoimmune diseases, but there are few data about the influence
of other diseases on the natural history of PBC. Thyroid
diseases have mainly an autoimmune aetiology, are often diagnosed
in women and can be associated with PBC. Aim: To
analyze the association between PBC and thyroid diseases
and the impact of these disorders on the natural history of
PBC in two European centres. Methods: 921 PBC patients
enrolled between 1969 and 2015 in Padova (376 patients,
M:F=25:351, mean follow-up 115.2 ± 85.6 months) and Barcelona
(545 patients, M:F=42:503, mean follow-up 135.0
± 94.9 months) were considered. Data on histological stage
at diagnosis, biochemical data, associated thyroid disorders,
extrahepatic autoimmune conditions, clinical events including
hepatic decompensation (ascites, spontaneous bacterial
peritonitis, encephalopathy, variceal bleeding and HCC
development) were recorded. Survival was analysed using
Kaplan-Meier curves and Cox regression method. Results: 150
patients (16.3 %) had a thyroid disorder: 94 patients (10.2 %)
had Hashimoto’s thyroiditis, 15 (1.6 %) had Graves’ disease,
22 (2.4 %) had a multi-nodular goitre, 7 (0.8 %) had thyroid
cancer, 13 (1.4 %) had other thyroid disorders. The prevalence
of different types of thyroid disease was similar in Padova and
Barcelona, except for Graves’ thyroiditis and thyroid cancer
that resulted more frequent in the Padova cohort (15.7% vs
5.0% and 8.6% vs 1.3% respectively, p